Meeting
2014 ASCO Annual Meeting
Phase II study of biomarker guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on EGFR-mutation status.
Authors
Wenzhao Zhong
Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China
Wenzhao Zhong , Xue-Ning Yang , Xuchao Zhang , Jian Su , Hong-Hong Yan , Zhihong Chen , Riqiang Liao , Qiang Nie , Song Dong , Yi-Long Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT00600587
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7572)
DOI
10.1200/jco.2014.32.15_suppl.7572
Abstract #
7572
Poster Bd #
180
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).
First Author: Caicun Zhou
Poster
2017 ASCO Annual Meeting
Updated survival outcomes of NEJ005/TCOG0902, a randomized phase II study of concurrent (C) versus sequential alternating (S) gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations.
First Author: Satoshi Oizumi
Poster
2015 ASCO Annual Meeting
Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303).
First Author: Karen L. Reckamp